Philipp Halbfass

Philipp Halbfass

Auto-generated profile, based on publicly available information

Philipp Halbfass

Clinic for Invasive Electrophysiology Heart Center Bad Neustadt Bad Neustadt a.d. Saale Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2015 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
TDThomas Deneke
Thomas Deneke
PJPierre Jais
Pierre Jais
MSMarco Scaglione
Marco Scaglione
RSRainer Schmitt
Rainer Schmitt
LBLuigi DI Biase
Luigi DI Biase
DHDavid Haines
David Haines

1 July 2015 in Heart Rhythm
Verified
Journal Article
Closed access
PMPatrick Müller
Patrick Müller
Johannes W. DietrichJohannes W. Dietrich
Johannes W. Dietrich
PHPhilipp Halbfass
Philipp Halbfass
AAAly Abouarab
Aly Abouarab
FFFranziska Fochler
Franziska Fochler
TDThomas Deneke
Thomas Deneke

1 August 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
PHPhilipp Halbfass
Philipp Halbfass
BPBorche Pavlov
Borche Pavlov
PMPatrick Müller
Patrick Müller
KNKarin Nentwich
Karin Nentwich
KSKai Sonne
Kai Sonne
TDThomas Deneke
Thomas Deneke
Background—: Up to 40% of patients demonstrate endoscopically detected asymptomatic esophageal lesions (EDEL) after atrial fibrillation ablation. Methods and Results—: Patients undergoing first atrial fibrillation ablation and postinterventional esophageal endoscopy were included in the study. Occurrence of esophageal perforating complications during follow-up was related to documented EDEL (category 1: erythema/erosion; category 2: ulcer). In total, 1802 patients underwent first atrial fibrillation ablation procedure between January 2013 and August 2016 at our institution. Out of this group, 832 patients (506 male patients, 61%; 64.0±10.0 years) with symptomatic paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural esophageal endoscopy. Patients were ablated using single-tip ablation with conventional or surround flow irrigation and circular ablation catheters with open irrigation (nMARQ). In 295 of 832 patients (35%), a temperature probe was used. EDEL occurred in 150 patients (18%; n=98 category 1 EDEL, n=52 category 2 EDEL). In 5 of 832 patients (0.6%), an esophageal perforation (n=3) or an esophagopericardial or atrioesophageal fistula (n=2) occurred 15 to 28 days (19±6 days) after ablation. Two patients (1 atrioesophageal fistula and 1 esophagopericardial fistula) died. Esophageal perforation occurred only in patients with category 2 lesions (absolute risk, 9.6%). In a logistic regression analysis, ulcers were identified to be a significant predictor for esophageal perforating complications. Conclusions—: Postablation endoscopy seems to identify patients at high risk of esophageal perforating complications only occurring in patients with category 2 EDEL. One out of 10 postablation esophageal ulcers progressed to perforation, and no patient without esophageal thermal ulcers showed the occurrence of perforating esophageal complications.

1 February 2019 in Heart Rhythm
Verified
Journal Article
Closed access
BYBharath Yarlagadda
Bharath Yarlagadda
TDThomas Deneke
Thomas Deneke
MTMohit Turagam
Mohit Turagam
TDTawseef Dar
Tawseef Dar
SPSwathi Paleti
Swathi Paleti
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy

10 November 2021 in EP Europace
Verified
Journal Article
Closed access
PHPhilipp Halbfass
Philipp Halbfass
JWJean-Yves Wielandts
Jean-Yves Wielandts
SKSébastien Knecht
Sébastien Knecht
JWJean-Benoît Le Polain de Waroux
Jean-Benoît Le Polain de Waroux
RTRené Tavernier
René Tavernier
TDThomas Deneke
Thomas Deneke
Aims: Very high-power short-duration (vHPSD) via temperature-controlled ablation (TCA) is a new modality to perform radiofrequency pulmonary vein isolation (PVI), conceivably at the cost of a narrower safety margin towards the oesophagus. In this two-centre trial, we aimed to determine the safety of vHPSD-based PVI with specific emphasis on silent oesophageal injury. Methods and results: Ninety consecutive patients with atrial fibrillation (AF) underwent vHPSD-PVI (90 W, 3–4 s, TCA) using the QDOT MICRO catheter, in conjunction with the nGEN (Bad Neustadt, n = 45) or nMARQ generator (Bruges, n = 45). All patients underwent post-ablation oesophageal endoscopy. Procedural parameters and complications were recorded. A subgroup of 21 patients from Bad Neustadt underwent cerebral magnetic resonance imaging (cMRI) to detect silent cerebral events (SCEs). Mean age was 67 ± 9 years, 59% patients were male, and 66% patients had paroxysmal AF. Pulmonary vein isolation was obtained in all cases after 96 ± 29 min. No steam pop, cardiac tamponade, stroke, or fistula was reported. None of the 90 patients demonstrated oesophageal ulceration (0%). Charring was not observed in the nMARQ cohort (0% vs. 11% in the nGEN group). In 5 out of 21 patients (24%), cMRI demonstrated SCE (exclusively nGEN cohort). Conclusion: Temperature-controlled vHPSD catheter ablation allows straightforward PVI without evidence of oesophageal ulcerations or symptomatic complications. Catheter tip charring and silent cerebral lesions when using the nGEN generator have led to further modification.

1 July 2016 in JACC
Verified
Journal Article
Closed access
SMSanghamitra Mohanty
Sanghamitra Mohanty
CGCarola Gianni
Carola Gianni
PMPrasant Mohanty
Prasant Mohanty
PHPhilipp Halbfass
Philipp Halbfass
TMTamara Metz
Tamara Metz
ANAndrea Natale
Andrea Natale